glp 1 select trial GLP-1 and heart health: what the largest cardiovascular in non-diabetics actually found. The trial tested semaglutide in 17,600+ people who had established cardiovascular disease and obesity but no diabetes — SELECT Cardiovascular Trial Information |

While effective, both GLP-1 agonists and SGLT2 inhibitors should complement lifestyle interventions, including diet, exercise, and weight management

As always, a quick reminder to check in with your healthcare provider before starting any new medication, including semaglutide

Insurance companies often have specific criteria for covering medications like GLP-1s, especially since they are considered specialty drugs and can be costly

Cushing's syndrome, though rare, causes weight gain through cortisol excess that weight loss injections cannot adequately address

Medication can absolutely change appetite, but the quality of the weight loss, how much fat is lost versus how much muscle is preserved, is still largely determined by lifestyle factors

Diabetes Obes Metab (2021) 23(3):75462